Trusted Supply of Critical & Orphan Medicines, Worldwide!

Drug: Ziv-Aflibercept
Brand: Ziv-Aflibercept IV 100mg/4mL
Manufacturer /
TM Owner
Sanofi (sanofi-aventis U.S. LLC; EU: Sanofi Winthrop Industrie)
Origin: France

Ziv-Aflibercept IV 100mg/4mL Injection

Ziv-Aflibercept IV contains ziv-aflibercept for targeted cancer therapy management. Available from Apple Globalcare with worldwide delivery.
Strength: 100mg/4mL
Pack Size: 1s
Storage: 2°C to 8°C
Form: Injection

+91 900 500 9556

Global Shipping : Reliable Global Distribution Network

Express Delivery : Priority Shipping for Every Order

Secure Payments : Trusted Payment Protection System

Disclaimer
All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the 'Manufacturer/ TM Owner' section in compliance with statutory requirements. Read More

Secure Handling

24/7 Worldwide Support

Global Access

Worldwide Access to Health

Cold-Chain Expert

Excellence in Cold-Chain

Trusted Supply

Certified Medical Supply

Indications & Clinical Uses

  • Ziv-Aflibercept IV 100 mg/4 mL is not a brand name; the approved product is Zaltrap (ziv-aflibercept) 25 mg/mL concentrate for intravenous infusion, and this information comes from the Zaltrap label.
  • Ziv-aflibercept is a VEGF-blocking biologic that binds vascular endothelial growth factor and placental growth factor and so limits tumour blood vessel growth.
  • It is approved, in combination with FOLFIRI chemotherapy (irinotecan, 5-fluorouracil and folinic acid), for adults with metastatic colorectal cancer that is resistant to, or has progressed after, an oxaliplatin-containing regimen.
  • The US dose is 4 mg/kg by intravenous infusion over 1 hour every 2 weeks; it is given only by a healthcare professional in a clinic or hospital.
  • It is supplied as 100 mg/4 mL and 200 mg/8 mL vials, and the EU authorisation is held by Sanofi Winthrop Industrie.

Side Effects

  • Very common side effects (20% of patients or more) in the US label include low white blood cells (leukopenia 78%), diarrhea (69%), neutropenia (67%), protein in the urine (62%), raised liver enzymes, mouth sores (stomatitis 50%), fatigue (48%), low platelets (48%) and high blood pressure (41%).
  • Others include weight loss, decreased appetite, nosebleeds, abdominal pain, hoarse voice and headache.
  • Serious reactions include severe or fatal bleeding (any bleeding 38%), gastrointestinal perforation, fistula formation, impaired wound healing, arterial blood clots, severe high blood pressure, kidney protein loss, severe neutropenia, severe diarrhea with dehydration, and reversible posterior leukoencephalopathy syndrome (headache, confusion, seizures, vision changes).
  • The current US label has no boxed warning.
  • Report bleeding, severe abdominal pain, chest pain, severe headache or fever straight away.

Precautions & Warnings

  • Zaltrap is for intravenous infusion only and must never be given as an intravenous push or bolus.
  • It is given through a 0.2-micron polyethersulfone filter after dilution.
  • Blood counts are checked before each cycle, and treatment is delayed if neutrophils fall below 1.5 x 10 to the 9th per litre.
  • Blood pressure is checked every 2 weeks and urine protein is monitored.
  • Treatment is suspended at least 4 weeks before elective surgery and restarted no sooner than 4 weeks after, once the wound has healed.
  • It is stopped permanently for severe bleeding, gastrointestinal perforation, fistula, arterial thromboembolic events, hypertensive crisis, nephrotic syndrome, thrombotic microangiopathy or reversible posterior leukoencephalopathy.
  • It can cause fetal harm: use effective contraception during treatment and for 3 months after the last dose, and avoid breastfeeding.
  • The label lists no contraindications.
  • Vials are stored at 2 C to 8 C in the original carton.

Avoid Interactions

  • The US label reports no clinically important interactions between ziv-aflibercept and irinotecan, 5-fluorouracil or leucovorin, the FOLFIRI medicines it is given with; the side effects of the chemotherapy add to those of Zaltrap, so blood counts, diarrhea and hydration are watched closely.
  • No medicines that reduce its effect were identified in the label.
  • Pharmacy handling matters: dilute only in 0.9% sodium chloride or 5% dextrose to 0.6 to 8 mg/mL, use PVC bags containing DEHP or polyolefin bags, and never use PVDF or nylon filters.
  • Tell your care team about all medicines and supplements you take, especially blood thinners and blood pressure medicines, and about any planned surgery or dental work.

References

Frequently Asked Questions

Zaltrap (ziv-aflibercept) is used with FOLFIRI chemotherapy to treat adults with metastatic colorectal cancer that has resisted or progressed after an oxaliplatin-based regimen. It blocks VEGF, which limits tumour blood vessel growth. It is given only by healthcare professionals in a clinic or hospital, by infusion into a vein.

Simple Working Process

We have simplified the online drug ordering process into 4 easy steps to ensure
a safe, secure, and hassle-free experience for our customers.

Order Online

Place your order online and upload prescription in minutes with ease.

Order Confirmation

We verify your prescription and confirm your order quickly and securely.

Prescription Review

Reviewed by licensed pharmacists. Carefully processed and validated.

R

Receive Medicines

Approved order delivered fast, easy, and right to your doorstep or nearby Airport.

Global Standards. Trusted Care.

Trusted & Reliable – Your Partner in Global Distribution.

We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.